Literature DB >> 11948053

Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in patients with congestive heart failure.

Naoko Mabuchi1, Takayoshi Tsutamoto, Atsuyuki Wada, Masato Ohnishi, Keiko Maeda, Masaru Hayashi, Masahiko Kinoshita.   

Abstract

STUDY
OBJECTIVES: We evaluated whether interleukin (IL)-6 is produced in the pulmonary circulation and investigated the relationship between IL-6 spillover in the lung and pulmonary vascular resistance (PVR) in patients with congestive heart failure (CHF). PATIENTS AND
INTERVENTIONS: Blood samples were obtained from the main pulmonary artery and pulmonary capillary wedge region in 50 patients with symptomatic left ventricular dysfunction, who had undergone cardiac catheterization, and 9 age-matched control subjects. Plasma IL-6, tumor necrosis factor-alpha, norepinephrine (NE), endothelin-1, atrial and brain natriuretic peptide, and cyclic guanosine monophosphate (cGMP) levels were determined. MEASUREMENTS AND
RESULTS: Plasma IL-6 concentrations were significantly higher in the pulmonary capillary wedge region than in the main pulmonary artery in both control subjects and patients with CHF. IL-6 production in the lung increased markedly in patients with severe CHF compared with control subjects and patients with mild CHF. Among hemodynamic variables, neurohumoral factors, and medications, plasma NE levels (p < 0.0001) showed an independent and significant positive relationship with IL-6 production in the lung, and treatment with beta-blockers (p = 0.004) showed an independent and significant negative relationship with IL-6 production in the lung. There was a significant positive correlation between IL-6 production in the lung and both PVR (r = 0.43; p = 0.001) and cGMP production in the lung (r = 0.498; p < 0.0001).
CONCLUSION: IL-6 production in the pulmonary circulation increases with the severity of CHF and is mainly associated with the activation of the sympathetic nervous system. The local production of IL-6 in the lung may modify PVR in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948053     DOI: 10.1378/chest.121.4.1195

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

Review 1.  Systemic inflammation in heart failure--the whys and wherefores.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Oie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

Review 2.  [Renal dysfunction in heart failure and hypervolumenia : Importance of congestion and backward failure].

Authors:  W Druml
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-10       Impact factor: 0.840

3.  Association of asthma-chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study.

Authors:  Jun-Jun Yeh; Yu-Feng Wei; Cheng-Li Lin; Wu-Huei Hsu
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.